Moving forward, perhaps no recent development in the use of RT in metastatic prostate cancer has captured greater attention than the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC).
Scott C. Morgan, MD, MSc, FRCPC
Advertisement
Articles by Scott C. Morgan, MD, MSc, FRCPC
Advertisement
Latest Updated Articles
- Palliative RT Research in Prostate Cancer: Understanding the Past, Anticipating the Future
Published: April 15th 2014 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
3
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
4
FDA Accepts NDA for New Nilotinib Formulation in CML
5
